Background: Hepatocellular carcinoma (HCC) is the most common hepatic malignancy and is one of the most prevalent cancers worldwide. The prognosis of late-stage HCC remains poor. The ImBrave 150 trial successfully demonstrated that overall survival (OS) and progression-free survival (PFS) was improv...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!